InDex Pharmaceuticals Holding AB (InDex) has completed a directed share issue of approximately SEK 140 million.  

The net proceeds of the directed share issue are intended to be used to advance the company’s lead drug candidate, cobitolimod, towards phase III as well as for general corporate purposes and financial flexibility.

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. 

Carnegie Investment Bank AB (publ) and Pareto Securities AB acted as Joint Bookrunners in connection with the directed share issue. Baker McKenzie acted as legal counsel to the Joint Bookrunners as to Swedish and US law. Baker McKenzie’s team mainly consisted of Joakim Falkner, Ian Gulam and Stefan Balazs in Stockholm and Megan Schellinger in London

Explore Our Newsroom